PART I . Overview We are a late-stage biotechnology company dedicated to unlocking the power of a patients own biology for the treatment of rare diseases. Our proprietary AIDE technology platform is an innovative drug/device combination that uses an automated process designed to encapsulate a drug into the patients own red blood cells. Red blood cells have several characteristics that make them an excellent vehicle for drug delivery, potentially including better safety and tolerability, enhanced...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-03-24 | 2024-12-31 | 0001662774-25-000012 | EDGAR | 102K words |
| 2024-04-01 | 2023-12-31 | 0000950170-24-039440 | EDGAR | — |
| 2023-03-15 | 2022-12-31 | 0000950170-23-008148 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0000950170-22-002571 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001564590-21-009867 | EDGAR | — |
| 2020-03-16 | 2019-12-31 | 0001564590-20-011165 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277529 | EDGAR | 30K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106535 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001662774-25-000032 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001662774-24-000011 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001662774-24-000005 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058201 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063716 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038042 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022241 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023877 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016102 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0000950170-22-009040 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-30 | 0001193125-26-130489 | EDGAR | 1K words |
| 2026-03-20 | 0001193125-26-117794 | EDGAR | — |
| 2026-02-12 | 0001193125-26-047544 | EDGAR | — |
| 2026-02-02 | 0001193125-26-033758 | EDGAR | — |
| 2026-01-29 | 0001193125-26-029524 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277523 | EDGAR | — |
| 2025-10-17 | 0001193125-25-242514 | EDGAR | — |
| 2025-09-26 | 0001193125-25-220722 | EDGAR | — |
| 2025-08-11 | 0000950170-25-106536 | EDGAR | — |
| 2025-07-16 | 0001193125-25-159886 | EDGAR | — |
109 total filings indexed. 81 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001662774 |
| Ticker | QNCX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | CA |
| Website | https://www.quincetx.com |
| Listed | 2019-05-09 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report